Urolithin A is a gut-derived metabolite produced when bacteria convert ellagitannins — compounds found in pomegranates, walnuts, and some berries — into a bioactive molecule the body can use. Interest in urolithin A has grown considerably because of its role in supporting mitophagy, the cellular process by which damaged mitochondria are identified and cleared so healthier ones can take their place. As with any compound moving from research labs into mainstream supplements, a reasonable first question is: how safe is it?
This article reviews what current human evidence says about urolithin A side effects, the tolerability data from clinical trials, and the honest limits of what researchers know so far. It does not constitute medical advice, and individuals with chronic health conditions or those taking medications should speak with a qualified healthcare provider before adding any new supplement.
Key Takeaways
- Urolithin A has been generally well tolerated in human clinical trials, including a randomised trial in older adults published in JAMA Network Open [2].
- Mild gastrointestinal discomfort is the most plausible short-term side effect, particularly when beginning supplementation.
- Urolithin A activates mitophagy — cellular mitochondrial renewal — which is biologically meaningful and warrants care in people with autoimmune conditions or those on immunosuppressive drugs.
- Long-term safety data over years of continuous use has not yet been established in the peer-reviewed literature.
- People who are pregnant, breastfeeding, or managing significant chronic illness should consult a healthcare provider before supplementing.
How Urolithin A Is Produced — and Why It Varies Between People
Urolithin A is not consumed directly from food in meaningful amounts. Instead, it is produced in the gut when intestinal bacteria metabolise ellagitannins and ellagic acid, precursors found in certain polyphenol-rich foods. Research has identified specific bacterial strains capable of this conversion — for example, Lactococcus garvieae FUA009 has been shown to produce urolithin A directly from ellagic acid [3]. This bacterial pathway matters for safety discussions because it means natural urolithin A exposure is highly individual: depending on a person’s microbiome composition, they may produce very little or a substantial amount even after eating the same foods.
Because gut microbial production is inconsistent across populations, supplement manufacturers have developed synthetic forms of urolithin A to deliver standardised doses. Understanding this distinction — natural gut production versus supplemental intake — is relevant when interpreting safety data, since trials use controlled doses rather than the variable amounts generated endogenously.
Clinical Trial Safety Data in Older Adults
One of the most rigorous pieces of human safety evidence comes from a randomised clinical trial published in JAMA Network Open, which examined urolithin A supplementation for muscle endurance and mitochondrial health in older adults. The trial monitored participants for adverse events over the course of the study, providing structured safety data from a controlled setting [2]. Findings from this kind of prospective, monitored trial are generally considered more reliable than anecdotal reports or short-term observational data.
A broader picture of tolerability across human studies is provided by a 2024 systematic review focused specifically on urolithin A in humans, which synthesised available evidence on both efficacy and safety outcomes in the context of aging-related research [4]. Systematic reviews that aggregate data across multiple trials are important because they can identify patterns in adverse events that individual studies may be underpowered to detect on their own.
Commonly Reported Side Effects
Across clinical studies conducted to date, urolithin A has generally been described as well tolerated in the doses tested. Gastrointestinal symptoms — such as mild nausea, loose stools, or abdominal discomfort — are among the most commonly noted complaints in supplement trials involving gut-active compounds, and urolithin A is no exception to the possibility of such effects, particularly when starting at higher doses.
It is worth distinguishing between effects that are directly caused by urolithin A and those that reflect how the broader gut environment responds to shifts in microbial metabolite production. Because urolithin A is itself a gut-derived metabolite and has been shown to interact with immune and inflammatory signalling pathways [6], temporary digestive adjustment at the start of supplementation is plausible and not necessarily a signal of harm.
No serious drug-like toxicity has been identified in human studies at the doses used in clinical trials. That said, the number of large, long-duration trials remains modest, and absence of identified harm is not the same as a confirmed clean safety record across all populations and all dose levels.
The Mechanism Behind Urolithin A — and What It Means for Safety
Urolithin A works primarily by activating mitophagy — the selective autophagy process through which cells tag dysfunctional mitochondria for degradation and recycling. This renewal pathway is central to why urolithin A is studied for applications in muscle health, neurological conditions, and aging [5]. Understanding this mechanism matters for safety because compounds that modulate autophagy are biologically active at a cellular level and, in theory, could have unintended effects if taken at very high doses or by people with conditions that already affect cellular clearance pathways.
Research into urolithin A’s immunomodulatory properties adds another layer of relevant context: gut metabolites including urolithin A have been studied for their roles in regulating immune responses [6]. While this is part of the scientific rationale for its potential health benefits, it also means individuals with autoimmune conditions or those on immunosuppressive therapies should consider discussing supplementation with a physician before starting.
What We Do Not Yet Know: Gaps in the Long-Term Evidence
The honest picture of urolithin A safety is that existing clinical trials, while encouraging, are relatively short in duration and involve specific populations — typically healthy middle-aged to older adults. The systematic review of human trials published in 2024 captures the current state of the evidence, which is still accumulating [4]. Long-term safety data over years of continuous use has not been established in the peer-reviewed literature.
Safety data in pregnant or breastfeeding individuals, children, people with significant liver or kidney impairment, or those on complex medication regimens is not available from current trials. Extrapolating from general-population trial data to these groups is not appropriate, and caution is warranted.
Urolithin A from Food Versus Supplements: Does the Source Matter for Safety?
When urolithin A is produced endogenously from dietary ellagitannins, the amounts generated are modest and self-limiting — constrained by food intake, microbial capacity, and absorption. Production in ruminants fed ellagitannin-rich plants has been documented as a naturally occurring process [1], suggesting the metabolite is well-handled by mammalian biology when generated through normal dietary pathways.
Supplements, however, deliver fixed and often higher doses than most people would generate from food alone. This is deliberate — the rationale is to ensure a consistent mitophagy-activating dose regardless of microbiome composition — but it also means that the safety ceiling established by natural dietary exposure cannot simply be assumed to cover supplemental doses. Sticking to tested dosage ranges and following manufacturer guidance is prudent until more long-term data are available.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day — The clinically studied form (Amazentis); used in the human trials. - DoNotAge Pure Urolithin A
capsules, 250-500 mg — Popular longevity-brand generic, third-party tested. - ProHealth Longevity Urolithin A
capsules, 500 mg — Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg — Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The evidence base for urolithin A safety in humans is promising but still developing, with most trials being short-term and conducted in healthy older adults; findings should not be generalised to all populations. This article is for informational purposes only and does not constitute medical advice — consult a qualified healthcare provider before starting urolithin A supplementation, especially if you have a chronic health condition, are pregnant or breastfeeding, or take prescription medications.
Frequently Asked Questions
Is urolithin A safe to take daily?
Clinical trials have tested daily urolithin A supplementation and reported a generally favourable tolerability profile, including in older adults monitored over the course of a controlled study [2]. However, long-term daily use over years has not been evaluated in large trials, so the full picture of chronic daily use is not yet established.
Can urolithin A cause stomach problems?
Gastrointestinal symptoms such as mild nausea or loose stools are among the possible side effects of gut-active compounds, and urolithin A may cause digestive adjustment in some individuals, particularly at higher doses or when first starting. If symptoms are persistent or severe, stopping use and consulting a healthcare provider is the appropriate step.
Who should avoid urolithin A supplements?
People who are pregnant or breastfeeding, children, and individuals with serious liver or kidney disease have not been adequately studied. Those on immunosuppressive medications should also exercise caution, given urolithin A’s involvement in immune and inflammatory signalling pathways [6]. A doctor’s guidance is especially important in these groups.
How does urolithin A work in the body?
Urolithin A supports mitophagy — the process by which cells identify and clear out damaged mitochondria to make way for healthier ones. This mitochondrial renewal mechanism is why it is studied for applications in muscle health and aging [2], and it is also why the compound is considered biologically active rather than inert.
Does everyone produce urolithin A naturally?
No. Natural urolithin A production depends on gut bacteria capable of converting ellagitannins from food. Specific strains such as Lactococcus garvieae FUA009 have been identified as capable of this conversion [3], but microbiome composition varies considerably between individuals, meaning some people produce very little urolithin A even from a polyphenol-rich diet.
Is the urolithin A in supplements different from what the body makes?
Commercially available urolithin A supplements typically provide a standardised synthetic form of the same molecule the gut can produce from dietary precursors. The natural route of production in ruminants and humans has been documented [1], and the compound itself is structurally identical. The main difference is dose consistency — supplements deliver a fixed amount regardless of microbiome variation.
References
- González-Barrio R et al. Metabolism of oak leaf ellagitannins and urolithin production in beef cattle. Journal of agricultural and food chemistry (2012). PMID 22375726
- Liu S et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA network open (2022). PMID 35050355
- Mi H et al. Lactococcus garvieae FUA009, a Novel Intestinal Bacterium Capable of Producing the Bioactive Metabolite Urolithin A from Ellagic Acid. Foods (Basel, Switzerland) (2022). PMID 36076807
- Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
- Rudenko AY et al. Targeting autophagy via mitochondrial uncoupling: Discovery of novel serratin derivative as a potential therapeutic for Parkinson's disease. Biochimie (2026). PMID 41106537
- Luo W et al. Gut microbiota-derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy. Frontiers in immunology (2025). PMID 41357193
